Evidence map›Paper›PMID 42705857›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2026

[Advances in Radiomics for Immune Checkpoint Inhibitor-related Pneumonitis 
of Lung Cancer].

Dong Zhang, Li Peng, Tianming Zhang, Fanqi Wu, Hong Wang

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dong ZhangDepartment of Pulmonary and Critical Care Medicine, Lanzhou University Second Hospital, Lanzhou 730000, China.
Li PengDepartment of Pulmonary and Critical Care Medicine, Lanzhou University Second Hospital, Lanzhou 730000, China.
Tianming ZhangDepartment of Pulmonary and Critical Care Medicine, Lanzhou University Second Hospital, Lanzhou 730000, China.
Fanqi WuDepartment of Pulmonary and Critical Care Medicine, Lanzhou University Second Hospital, Lanzhou 730000, China.
Hong WangDepartment of Pulmonary and Critical Care Medicine, Lanzhou University Second Hospital, Lanzhou 730000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have significantly improved the prognosis of patients with lung cancer. However, checkpoint inhibitor-related pneumonitis (CIP), as one of the most severe immune-related adverse events, lacks well-defined diagnostic criteria and reliable risk stratification tools. Radiomics enables high-throughput feature extraction from computed tomography images and provides a non-invasive technical approach for the early identification and risk stratification of CIP. This article systematically reviews the recent advances in the application of radiomics to risk prediction, diagnosis and differential diagnosis, and prognostic evaluation of CIP in lung cancer immunotherapy. Furthermore, it explores the value of integrating radiomics with multi-omics data in elucidating the pathogenesis of CIP, as well as the role of explainable artificial intelligence (XAI) in enhancing the clinical trustworthiness of models.
.

Indexed as

Immune Checkpoint InhibitorsLung NeoplasmsPneumoniaRadiomicsHumansImmune Checkpoint InhibitorsCheckpoint inhibitor-related pneumonitisLung neoplasmRadiomics

Identifiers

PMID42705857
PMCPMC13559062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.